MedPath

Automated Breast Ultrasound Screening

Completed
Conditions
Breast Cancer
Registration Number
NCT02650778
Lead Sponsor
Northeastern Ohio Radiology Research and Education Fund
Brief Summary

Women with dense breasts (BIRADS 3 or 4) with a BIRADS category 1 or 2 mammogram are asked to participate in a automated volume breast ultrasound scanner. The study evaluates prospectively the changes in recall rate, positive biopsy rate, cancer detection rate when BIRADS category 3 lesions are given a 1 year follow-up recommendation.

Detailed Description

Women with dense breasts (BIRADS 3 or 4) with a BIRADS category 1 or 2 mammogram are asked to participate in a automated volume breast ultrasound scanner. If the women agrees to participate and sign informed consent she undergoes an automated whole breast scan. The scan is interpreted independent of the mammogram. Scans are assigned a BIRADS category score of 1, 2, 3,or 0. BIRADS category 3 lesions are reported as no evidence of malignancy and a 1 year follow-up is recommended. BIRADS category 0 lesions are requested to have a hand held ultrasound including elastography. Follow up is then determined by BIRADS score and elastography results of hand held ultrasound.

The study evaluates prospectively the changes in recall rate, positive biopsy rate, cancer detection rate when BIRADS category 3 lesions are given a 1 year follow-up recommendation.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
2257
Inclusion Criteria
  • Women age >18 scheduled for routine screening mammogram. Women with Density 3 or 4 and BIRADS category 1 or mammogram are asked to participate in study
Exclusion Criteria
  • Inability to give informed consent

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Decreased recall rate for screening breast ultrasound while maintaining cancer detection rate3 years
Secondary Outcome Measures
NameTimeMethod
Increased positive biopsy rate3 years
© Copyright 2025. All Rights Reserved by MedPath